S

Shanghai Rightongene Biotechnology Co Ltd
SSE:688217

Watchlist Manager
Shanghai Rightongene Biotechnology Co Ltd
SSE:688217
Watchlist
Price: 32.31 CNY 1.64% Market Closed
Market Cap: 1.8B CNY

Wall Street
Price Targets

Price Targets Summary
Shanghai Rightongene Biotechnology Co Ltd

There are no price targets for Shanghai Rightongene Biotechnology Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Shanghai Rightongene Biotechnology Co Ltd Competitors:
Price Targets
AMP
Amper SA
10% Upside
VINP
Vinci Partners Investments Ltd
11% Upside
IBEX
Ibex Ltd
10% Upside
HCAT
Health Catalyst Inc
71% Upside

Revenue
Forecast

-1% / Year
Past Growth
37% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
-1% / Year
Past Growth
37% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

For the last 5 years the compound annual growth rate for Shanghai Rightongene Biotechnology Co Ltd's revenue is -1%. The projected CAGR for the next 2 years is 37%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Shanghai Rightongene Biotechnology Co Ltd

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shanghai Rightongene Biotechnology Co Ltd's stock price target?
Not Available

Shanghai Rightongene Biotechnology Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Shanghai Rightongene Biotechnology Co Ltd's Revenue forecast?
Projected CAGR
37%

For the last 5 years the compound annual growth rate for Shanghai Rightongene Biotechnology Co Ltd's revenue is -1%. The projected CAGR for the next 2 years is 37%.

Back to Top